Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Direct detection of alpha synuclein oligomers in vivo.

Dimant H, Kalia SK, Kalia LV, Zhu LN, Kibuuka L, Ebrahimi-Fakhari D, McFarland NR, Fan Z, Hyman BT, McLean PJ.

Acta Neuropathol Commun. 2013 May 9;1:6. doi: 10.1186/2051-5960-1-6.

2.

AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.

Ip CW, Klaus LC, Karikari AA, Visanji NP, Brotchie JM, Lang AE, Volkmann J, Koprich JB.

Acta Neuropathol Commun. 2017 Feb 1;5(1):11. doi: 10.1186/s40478-017-0416-x.

3.

Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.

Moloney TC, Hyland R, O'Toole D, Paucard A, Kirik D, O'Doherty A, Gorman AM, Dowd E.

CNS Neurosci Ther. 2014 Jan;20(1):50-8. doi: 10.1111/cns.12200. Epub 2013 Nov 27.

PMID:
24279716
4.

rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.

Oliveras-Salvá M, Van der Perren A, Casadei N, Stroobants S, Nuber S, D'Hooge R, Van den Haute C, Baekelandt V.

Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44.

5.

Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.

Kirik D, Rosenblad C, Burger C, Lundberg C, Johansen TE, Muzyczka N, Mandel RJ, Björklund A.

J Neurosci. 2002 Apr 1;22(7):2780-91.

6.

Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.

Song LK, Ma KL, Yuan YH, Mu Z, Song XY, Niu F, Han N, Chen NH.

PLoS One. 2015 Jun 26;10(6):e0131281. doi: 10.1371/journal.pone.0131281. eCollection 2015.

7.

Enhanced ubiquitin-dependent degradation by Nedd4 protects against α-synuclein accumulation and toxicity in animal models of Parkinson's disease.

Davies SE, Hallett PJ, Moens T, Smith G, Mangano E, Kim HT, Goldberg AL, Liu JL, Isacson O, Tofaris GK.

Neurobiol Dis. 2014 Apr;64:79-87. doi: 10.1016/j.nbd.2013.12.011. Epub 2013 Dec 31.

8.

Genetic and pharmacological evidence that endogenous nociceptin/orphanin FQ contributes to dopamine cell loss in Parkinson's disease.

Arcuri L, Viaro R, Bido S, Longo F, Calcagno M, Fernagut PO, Zaveri NT, Calò G, Bezard E, Morari M.

Neurobiol Dis. 2016 May;89:55-64. doi: 10.1016/j.nbd.2016.01.016. Epub 2016 Jan 22.

9.

FOXO3 determines the accumulation of α-synuclein and controls the fate of dopaminergic neurons in the substantia nigra.

Pino E, Amamoto R, Zheng L, Cacquevel M, Sarria JC, Knott GW, Schneider BL.

Hum Mol Genet. 2014 Mar 15;23(6):1435-52. doi: 10.1093/hmg/ddt530. Epub 2013 Oct 24.

PMID:
24158851
10.

Age-dependent dopamine transporter dysfunction and Serine129 phospho-α-synuclein overload in G2019S LRRK2 mice.

Longo F, Mercatelli D, Novello S, Arcuri L, Brugnoli A, Vincenzi F, Russo I, Berti G, Mabrouk OS, Kennedy RT, Shimshek DR, Varani K, Bubacco L, Greggio E, Morari M.

Acta Neuropathol Commun. 2017 Mar 14;5(1):22. doi: 10.1186/s40478-017-0426-8.

11.

Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.

Decressac M, Mattsson B, Björklund A.

Exp Neurol. 2012 May;235(1):306-15. doi: 10.1016/j.expneurol.2012.02.012. Epub 2012 Feb 25.

PMID:
22394547
12.

Intrastriatal injection of pre-formed mouse α-synuclein fibrils into rats triggers α-synuclein pathology and bilateral nigrostriatal degeneration.

Paumier KL, Luk KC, Manfredsson FP, Kanaan NM, Lipton JW, Collier TJ, Steece-Collier K, Kemp CJ, Celano S, Schulz E, Sandoval IM, Fleming S, Dirr E, Polinski NK, Trojanowski JQ, Lee VM, Sortwell CE.

Neurobiol Dis. 2015 Oct;82:185-199. doi: 10.1016/j.nbd.2015.06.003. Epub 2015 Jun 17.

13.

shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.

Zharikov AD, Cannon JR, Tapias V, Bai Q, Horowitz MP, Shah V, El Ayadi A, Hastings TG, Greenamyre JT, Burton EA.

J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.

14.

Co-expression of C-terminal truncated alpha-synuclein enhances full-length alpha-synuclein-induced pathology.

Ulusoy A, Febbraro F, Jensen PH, Kirik D, Romero-Ramos M.

Eur J Neurosci. 2010 Aug;32(3):409-22. doi: 10.1111/j.1460-9568.2010.07284.x.

PMID:
20704592
15.

Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.

St Martin JL, Klucken J, Outeiro TF, Nguyen P, Keller-McGandy C, Cantuti-Castelvetri I, Grammatopoulos TN, Standaert DG, Hyman BT, McLean PJ.

J Neurochem. 2007 Mar;100(6):1449-57. Epub 2007 Jan 4.

16.
17.

Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Khodr CE, Becerra A, Han Y, Bohn MC.

Brain Res. 2014 Mar 6;1550:47-60. doi: 10.1016/j.brainres.2014.01.010. Epub 2014 Jan 21.

18.

Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.

Febbraro F, Andersen KJ, Sanchez-Guajardo V, Tentillier N, Romero-Ramos M.

Exp Neurol. 2013 Sep;247:45-58. doi: 10.1016/j.expneurol.2013.03.017. Epub 2013 Mar 24.

PMID:
23531432
19.

Tea polyphenols alleviate motor impairments, dopaminergic neuronal injury, and cerebral α-synuclein aggregation in MPTP-intoxicated parkinsonian monkeys.

Chen M, Wang T, Yue F, Li X, Wang P, Li Y, Chan P, Yu S.

Neuroscience. 2015 Feb 12;286:383-92. doi: 10.1016/j.neuroscience.2014.12.003. Epub 2014 Dec 10.

PMID:
25498223
20.

Late-onset Parkinsonism in NFκB/c-Rel-deficient mice.

Baiguera C, Alghisi M, Pinna A, Bellucci A, De Luca MA, Frau L, Morelli M, Ingrassia R, Benarese M, Porrini V, Pellitteri M, Bertini G, Fabene PF, Sigala S, Spillantini MG, Liou HC, Spano PF, Pizzi M.

Brain. 2012 Sep;135(Pt 9):2750-65. doi: 10.1093/brain/aws193. Epub 2012 Aug 21.

Supplemental Content

Support Center